has a crucial impact on morbidity and mortality after cerebral ischemic injury as it aggravates already impaired compliance and contributes to additional ischemic injuries due to reduced perfusion and oxygenation.
The main pre-specified endpoints in the study include the numbers of patients with ICH and brain edema
, and clinical stroke outcome assessed by the modified Rankin scale (mRS) and the NIH stroke scale (NIHSS) up to 30 days following stroke.
This vasogenic edema was remarkably amenable to reduction by steroids, and often occurred without changes in ICP or reduction in CT-evident brain edema
: In the initial surgery trial, brain edema
was noted in 22.
THR-18 binding uncouples the clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects on the blood vessel wall, including intracranial hemorrhage and brain edema
This study is open to all patients who participate in one of the two ongoing blinded, Phase III trials designed to determine the dexamethasone-sparing effects of hCRF in brain tumor patients being treated for peritumoral brain edema
Abe K, Yuki S, Kogure K: Strong attenuation of ischemic and postischemic brain edema
by a novel free radical scavenger.
Side effects that have been reported in patients receiving Gliadel Wafer include seizures, intracranial infections, abnormal wound healing, and brain edema
OCR-002 data presented at EASL, AASLD, and ISHEN in 2010 have confirmed that OCR-002 can consistently lower ammonia in multiple preclinical models of cirrhosis and acute liver failure and has been correlated with normalization of intracranial pressure, brain edema
and neurologic function.
NTI is also developing XERECEPT(TM), a synthetic preparation of the natural peptide, Corticotropin Releasing Factor (CRF), as a treatment for peritumoral brain edema
XERECEPT has shown in Phase II and Phase III studies that it may provide a safe and effective alternative to corticosteroid treatment for tumor-related brain edema
and that it may also have direct anti-tumor activity.
NASDAQ:NTII) today announced that interim results of one of the company's ongoing Phase I/II trials of Corticotropin-Releasing Factor (CRF) for peritumoral brain edema
were presented at the American Association of Cancer Research meeting in Washington, DC.
AST-120 is an attractive treatment option for MHE because of its well-established safety profile, and its demonstrated ability to reduce circulating ammonia levels and brain edema
in a model of cirrhosis.
NTII is evaluating CRF for the treatment of several clinical indications including brain edema
resulting from tumors and rheumatoid arthritis.
Over the next several months, we expect to report on the trial results of our lead drug candidate, Corticotropin-Releasing Factor (CRF), in rheumatoid arthritis, asthma, and brain edema
, and to proceed to more extensive efficacy trials for one or more of these indications.